Board of Directors
Kapil Dhingra, MB, BS
Director – Chairman
Kapil Dhingra is is managing member of KAPital Consulting, a healthcare consulting firm he founded in 2008, which provides oncology-related strategic consulting services to biopharmaceutical companies. From 1999 to 2008, he served in positions of increasing responsibility at Hoffmann-La Roche, Inc., including Vice President, head, Oncology Disease Biology Leadership team; and head, Oncology Clinical Development. He also worked as a senior clinical research physician at Eli Lilly. Before and during his tenures at both Eli Lilly and Hoffmann-LaRoche, Dr. Dhingra maintained an active academic career first as an Assistant Professor at MD Anderson Cancer Center, then as a Clinical Associate Professor at Indiana University School of Medicine and, most recently, as a clinical affiliate at Memorial Sloan Kettering Cancer Center. Dr. Dhingra also serves on several emerging life science company boards. He received his MB, BS degrees (equivalent to an MD degree in the USA) from the All India Institute of Medical Sciences.
Chief Executive Officer
John Boyce is an energetic leader and serial entrepreneur who has successfully raised over $100MM in funding from venture capital and private investors. Most recently, Mr. Boyce was the President and Chief Executive Officer (CEO) of GnuBIO, Inc, a desktop DNA sequencing company that he co-founded in January 2011. Mr. Boyce raised a total of $18MM over two rounds of investor funding and based on the clinical strategy and product roll out initiative that he put in place, GnuBIO was acquired by Bio-Rad in April 2014 for a deal valued at $110MM. Prior to GnuBIO, Mr. Boyce started and sold Affomix (a digital proteomics company) to Illumina resulting in a significant return on investment for investors and shareholders within two years. Through the course of his career, he served in key positions in numerous life sciences companies to drive them either towards an acquisition or an IPO. Mr. Boyce also conceived, founded, and ran the Consumer Genetics Conference, which was acquired by Cambridge Healthtech Institute in 2012. In 2013, Mr. Boyce was awarded the honor as one of the top 15 technology luminaries in Massachusetts by the Boston Business Journal and Mass High Technology. In 2014, Mr. Boyce was made a Fellow at Harvard University and teaches "Innovation in Science and Engineering" (ES-139).
Peter Johann, PhD
Peter Johann is a Managing General Partner of NGN Capital. He joined NGN Capital from Boehringer Ingelheim, where he was the Division Head of Corporate Development responsible for strategic planning, strategic projects, M&A, business development and licensing. Prior to this, Dr. Johann served at F. Hoffmann-La Roche as Global Business Leader where he led global business teams and was responsible for global marketing of oncology products as well as evaluation of pipeline products from internal and external sources. Dr. Johann joined Roche from Boehringer Mannheim, where he was Head of Business Development and Marketing Molecular Medicine. He obtained his PhD from the Technical University Munich. Dr. Johann holds Board seats with Cerapedics (Observer), Exosome, Horizon Pharma, Micromet, Resverlogix, Vivaldi Biosciences and held Board and Observer seats at Jerini and Santhera respectively.
Geert-Jan Mulder, MD
Geert-Jan Mulder, co-founded Forbion in 2006 and currently serves on the Board of several Forbion portfolio companies. In addition, Dr. Mulder led the firm’s successful investment in bluebirdbio (NASDAQ: BLUE), which went public in 2013, where he supported the company in clinical development and served as the chairman for several years. Other investments include Acorda Therapeutics (NASDAQ:ACOR), which went public in 2006 where he was part of the AMPYRA® (dalfampridine) board panel to evaluate a new clinical endpoint in multiple sclerosis; PanGenetics B.V., which sold to Abbott, where he led the Series B financing round; and Transave, where he supported the company’s clinical development for ARIKAYCE® (liposomal amikacin for inhalation) partly as interim CMO and also served on the Board of Directors until the merger with Insmed (NASDAQ:INSM) in 2010. Prior to joining ABN AMRO Capital Life Sciences (Forbion’s predecessor) in 2001, Dr. Mulder received his medical degree from the University of Utrecht (NL) and spent two years as a clinician in Obstetrics and Gynecology at the University Medical Center of Utrecht (UMC). He then joined Searle (now Pfizer) working in the field of arthritis and pain, involved in clinical development as well as in the European Advocacy Development for the pre-launch of Celebrex®. After transitioning to Byk Gulden (now Takeda), he became Clinical Research Manager, where his department was responsible for the design and execution of numerous early and late stage clinical trials that formed the basis for two global product registrations, i.e., Daxas® and Alvesco® in the field of Respiratory Medicine (asthma and COPD). He was a member of the Global Medical Marketing group of their Respiratory Franchise and was involved in the line extension program for Pantozol®.
Joseph Slattery joined the Exosome Diagnostics Board of Directors in June 2013 and has served as the Chairman of our Audit Committee since October 2013. He is currently the Executive Vice President and Chief Financial Officer at TransEnterix, Inc., a publicly held company focused on surgical robotics. He also serves on the Board of Directors of CVRx, Inc., and Replimune Group, Inc.. Mr. Slattery previously served as a Director, Chairman of the Audit Committee and member of the Nominating & Governance Committee of Micromet, Inc., and as a Director and Chairman of the Audit Committee of Baxano Surgical, Inc., where he also served separately as Executive Vice President and Chief Financial officer. Mr. Slattery was also Chief Financial Officer and Senior Vice President, Digene Corporation. Mr. Slattery received a B.S. degree in Accountancy from Bentley University and is a Certified Public Accountant.
Steven Soignet, MD
Steven Soignet is a co-founder of Arcus Ventures. In 2003, he became a venture partner of Cross Atlantic Partners, a healthcare and biotechnology venture capital fund. Dr. Soignet held a faculty appointment in the Developmental Chemotherapy Service at Memorial Sloan-Kettering Cancer Center, and in the Department of Medicine at Cornell University Medical Center. His primary research focus was in early phase clinical drug development in both hematological and solid tumors. He was a lead investigator of a Pilot and a large USA Multicenter Trial that led to FDA and European approval of arsenic trioxide for the treatment of relapsed acute promyelocytic leukemia. Dr. Soignet’s research has been published in the New England Journal of Medicine, Leukemia, Blood, Journal of Clinical Oncology and Clinical Cancer Research. Dr. Soignet received his B.S. from the University of New Orleans, and his MD (AOA, honors) from Louisiana State University School of Medicine. His fellowship training was in medical oncology/hematology at Memorial Sloan-Kettering Cancer Center.